{"id":5947,"date":"2025-06-09T16:58:29","date_gmt":"2025-06-09T16:58:29","guid":{"rendered":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/?page_id=5947"},"modified":"2025-12-08T20:10:12","modified_gmt":"2025-12-08T20:10:12","slug":"shareholders","status":"publish","type":"page","link":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/","title":{"rendered":"Shareholders"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"5947\" class=\"elementor elementor-5947 elementor-392\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8225e97 e-flex e-con-boxed e-con e-parent\" data-id=\"8225e97\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-75f2dba elementor-widget__width-initial elementor-widget elementor-widget-heading\" data-id=\"75f2dba\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Shareholders<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-42e3287 elementor-widget elementor-widget-button\" data-id=\"42e3287\" data-element_type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"\/en\/investor-relations\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 25 24\" transform=\"rotate(0 0 0)\"><path d=\"M15.2335 5.21967C15.5263 5.51256 15.5263 5.98744 15.2335 6.28033L9.51379 12L15.2335 17.7197C15.5263 18.0126 15.5263 18.4874 15.2335 18.7803C14.9406 19.0732 14.4657 19.0732 14.1728 18.7803L7.92279 12.5303C7.6299 12.2374 7.6299 11.7626 7.92279 11.4697L14.1728 5.21967C14.4657 4.92678 14.9406 4.92678 15.2335 5.21967Z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Go back to Investor Relations<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-c495c07 e-grid half-bottom-padding e-con-boxed e-con e-parent\" data-id=\"c495c07\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3fc1b22 elementor-widget elementor-widget-jet-pie-chart\" data-id=\"3fc1b22\" data-element_type=\"widget\" data-widget_type=\"jet-pie-chart.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-jet-pie-chart jet-elements\"><div class=\"jet-pie-chart-title-container\"><h5 class=\"jet-pie-chart-title\"><\/h5><\/div>\n\t\t<div class=\"jet-pie-chart-container\" data-chart=\"{&quot;datasets&quot;:[{&quot;data&quot;:[9.56,9.14,8.11,7.43,5.22,60.54],&quot;backgroundColor&quot;:[&quot;#247A52&quot;,&quot;#2AC17B&quot;,&quot;#36B57A&quot;,&quot;#032247&quot;,&quot;#053978&quot;,&quot;#085DC4&quot;],&quot;borderWidth&quot;:2,&quot;borderColor&quot;:&quot;#ffffff&quot;,&quot;hoverBorderColor&quot;:&quot;#ffffff&quot;}],&quot;labels&quot;:[&quot;Kvarko Group ASI Sp. z o.o.,&quot;,&quot;TOTAL Fundusz Inwestycyjny Zamkni\\u0119ty&quot;,&quot;TFI PZU SA&quot;,&quot;\\u0141ukasz Bzdzion&quot;,&quot;Alternative Solution ASI S.A., &quot;,&quot;Pozostali&quot;]}\" data-options=\"{&quot;animation&quot;:{&quot;duration&quot;:1,&quot;easing&quot;:&quot;linear&quot;,&quot;animateScale&quot;:false},&quot;legend&quot;:{&quot;display&quot;:false,&quot;position&quot;:&quot;bottom&quot;,&quot;reverse&quot;:false,&quot;align&quot;:&quot;center&quot;},&quot;tooltips&quot;:{&quot;enabled&quot;:true,&quot;backgroundColor&quot;:&quot;#F2F2F2&quot;,&quot;bodyFontFamily&quot;:&quot;Poppins&quot;,&quot;bodyFontSize&quot;:16,&quot;bodyFontColor&quot;:&quot;#292929&quot;}}\" data-tooltip=\"%\">\n\t\t\t<canvas class=\"jet-pie-chart\" role=\"img\"><\/canvas>\n\t\t<\/div>\n\n\t\t<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3592370 tabela-akcjonariat elementor-widget elementor-widget-text-editor\" data-id=\"3592370\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<table>\n<thead>\n<tr>\n<td><\/td>\n<td>Shareholder<\/td>\n<td>No of shares<\/td>\n<td>% of shares<\/td>\n<td>No of votes<\/td>\n<td>% of votes<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>TFI PZU SA<\/td>\n<td>775.437<\/td>\n<td>14,41%<\/td>\n<td>775.437<\/td>\n<td>14,41%<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>TOTAL Fundusz Inwestycyjny Zamkni\u0119ty<\/td>\n<td>479.500<\/td>\n<td>8,91%<\/td>\n<td>479.500<\/td>\n<td>8,91%<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>\u0141ukasz Bzdzion<\/td>\n<td>365.763<\/td>\n<td>6,80%<\/td>\n<td>365.763<\/td>\n<td>6,80%<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Kvarko Group ASI Sp. z&nbsp;o.o.<\/td>\n<td>320.953<\/td>\n<td>5,96%<\/td>\n<td>320.953<\/td>\n<td>5,96%<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Alternative Solution ASI S.A.<\/td>\n<td>256.832<\/td>\n<td>5,22%<\/td>\n<td>256.832<\/td>\n<td>5,22%<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Other shareholders &lt; 5,00%<\/td>\n<td>3.440.600<\/td>\n<td>63,92%<\/td>\n<td>3.440.600<\/td>\n<td>63,92%<\/td>\n<\/tr>\n<\/tbody>\n<tfoot>\n<tr>\n<td><\/td>\n<td>Total<\/td>\n<td>5.382.253<\/td>\n<td>100,00%<\/td>\n<td>5.382.253<\/td>\n<td>100,00%<\/td>\n<\/tr>\n<\/tfoot>\n<\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-472ee13 e-grid half-top-padding e-con-boxed e-con e-parent\" data-id=\"472ee13\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-59d6115 e-con-full e-flex e-con e-child\" data-id=\"59d6115\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-78b871f elementor-widget elementor-widget-text-editor\" data-id=\"78b871f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>The company is registered in the Register of Entrepreneurs of the National Court Register maintained by the District Court for Wroc\u0142aw-Fabryczna in Wroc\u0142aw, 6th Commercial Division of the National Court Register, under number 0000744521.<\/p><p>REGON: 364963245<br \/>NIP: 8992794360<\/p><p>Registered share capital amount: 538 225,30 PLN<\/p><p>Amount of paid-up share capital: 92 446,80 PLN<\/p><p>Nominal value of one share: 0,10 PLN<\/p><p>Number of shares: 4 929 468<\/p><p>ISIN Code: PLBCLTX00019<\/p><p>GPW Ticker: BCX<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c8da26d elementor-widget elementor-widget-image\" data-id=\"c8da26d\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"512\" height=\"385\" src=\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat.jpg\" class=\"attachment-full size-full wp-image-5437\" alt=\"\" srcset=\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat.jpg 512w, https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat-300x226.jpg 300w\" sizes=\"(max-width: 512px) 100vw, 512px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Shareholders Go back to Investor Relations Shareholder No of shares % of shares No of votes % of votes 1 TFI PZU SA 775.437 14,41% 775.437 14,41% 2 TOTAL Fundusz Inwestycyjny Zamkni\u0119ty 479.500 8,91% 479.500 8,91% 3 \u0141ukasz Bzdzion 365.763 6,80% 365.763 6,80% 4 Kvarko Group ASI Sp. z&nbsp;o.o. 320.953 5,96% 320.953 5,96% 5 Alternative [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":5934,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5947","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Shareholders - Bioceltix<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders - Bioceltix\" \/>\n<meta property=\"og:description\" content=\"Shareholders Go back to Investor Relations Shareholder No of shares % of shares No of votes % of votes 1 TFI PZU SA 775.437 14,41% 775.437 14,41% 2 TOTAL Fundusz Inwestycyjny Zamkni\u0119ty 479.500 8,91% 479.500 8,91% 3 \u0141ukasz Bzdzion 365.763 6,80% 365.763 6,80% 4 Kvarko Group ASI Sp. z&nbsp;o.o. 320.953 5,96% 320.953 5,96% 5 Alternative [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Bioceltix\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T20:10:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"385\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/\",\"url\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/\",\"name\":\"Shareholders - Bioceltix\",\"isPartOf\":{\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat.jpg\",\"datePublished\":\"2025-06-09T16:58:29+00:00\",\"dateModified\":\"2025-12-08T20:10:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/#primaryimage\",\"url\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat.jpg\",\"contentUrl\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Strona g\u0142\u00f3wna\",\"item\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investor Relations\",\"item\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#website\",\"url\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/\",\"name\":\"Bioceltix\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#organization\",\"name\":\"Bioceltix\",\"url\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/05\/logo-bioceltix.png\",\"contentUrl\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/05\/logo-bioceltix.png\",\"width\":274,\"height\":73,\"caption\":\"Bioceltix\"},\"image\":{\"@id\":\"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders - Bioceltix","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Shareholders - Bioceltix","og_description":"Shareholders Go back to Investor Relations Shareholder No of shares % of shares No of votes % of votes 1 TFI PZU SA 775.437 14,41% 775.437 14,41% 2 TOTAL Fundusz Inwestycyjny Zamkni\u0119ty 479.500 8,91% 479.500 8,91% 3 \u0141ukasz Bzdzion 365.763 6,80% 365.763 6,80% 4 Kvarko Group ASI Sp. z&nbsp;o.o. 320.953 5,96% 320.953 5,96% 5 Alternative [&hellip;]","og_url":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/","og_site_name":"Bioceltix","article_modified_time":"2025-12-08T20:10:12+00:00","og_image":[{"width":512,"height":385,"url":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/","url":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/","name":"Shareholders - Bioceltix","isPartOf":{"@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/#primaryimage"},"image":{"@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat.jpg","datePublished":"2025-06-09T16:58:29+00:00","dateModified":"2025-12-08T20:10:12+00:00","breadcrumb":{"@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/#primaryimage","url":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat.jpg","contentUrl":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/06\/akcjonariat.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/shareholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Strona g\u0142\u00f3wna","item":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/"},{"@type":"ListItem","position":2,"name":"Investor Relations","item":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/investor-relations\/"},{"@type":"ListItem","position":3,"name":"Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#website","url":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/","name":"Bioceltix","description":"","publisher":{"@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#organization","name":"Bioceltix","url":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#\/schema\/logo\/image\/","url":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/05\/logo-bioceltix.png","contentUrl":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/wp-content\/uploads\/2025\/05\/logo-bioceltix.png","width":274,"height":73,"caption":"Bioceltix"},"image":{"@id":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/wp-json\/wp\/v2\/pages\/5947","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/wp-json\/wp\/v2\/comments?post=5947"}],"version-history":[{"count":28,"href":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/wp-json\/wp\/v2\/pages\/5947\/revisions"}],"predecessor-version":[{"id":6940,"href":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/wp-json\/wp\/v2\/pages\/5947\/revisions\/6940"}],"up":[{"embeddable":true,"href":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/wp-json\/wp\/v2\/pages\/5934"}],"wp:attachment":[{"href":"https:\/\/nervous-vaughan.46-242-130-154.plesk.page\/en\/wp-json\/wp\/v2\/media?parent=5947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}